ITT Aktie

 

Basel, 18 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III evERA Breast Cancer study. Data showed giredestrant in combination with everolimus significantly reduced the risk of disease progression or death (progression-free survival; PFS) by 44% and 62% in the intention-to-treat (ITT) and ESR1-mutated populations, respectively, compared with standard-of-care endocrine therapy plus everolimus.1 The evERA study is evaluating the investigational giredestrant combination in people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer previously treated with cyclin-dependent kinase (CDK) 4/6 inhibitor and endocrine therapy.2 This is the first positive head-to-head phase III trial investigating a selective oestrogen receptor degrader-containing regimen versus a standard-of-care combination.2 The results are being presented in an oral session at the European Society for Medi...

read more...

ITT (ITT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....

Intel has unveiled its most ambitious artificial intelligence (AI) roadmap to date, featuring the next-generation Panther Lake AI PC processor, Clearwater Forest server processor, and a comprehensive AI execution plan. At the recent Intel Tech Tour (ITT) keynote, the company's new Chief AI and Technology Officer, Sachin Katti, announced that Intel will adopt an "annual update" cadence for its AI product lineup, marking a strategic shift toward faster iteration and innovation....

Diversified operations rebound as MMM, ITT, and STRR capitalize on aerospace, defense, industrial growth, innovation, and major infrastructure projects....

The Zacks Diversified Operations industry participants stand to gain from strength across the aerospace, defense, and oil and gas industries. MMM, ITT and STRR are notable stocks in the industry....

- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. HONG KONG, Oct.......

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

Does ITT (ITT) have what it takes to be a top stock pick for momentum investors? Let's find out....

ITT (ITT) possesses solid growth attributes, which could help it handily outperform the market....

Latest Ratings for ITT DateFirmActionFromTo Dec 2021B of A SecuritiesUpgradesNeutralBuy Aug 2021OppenheimerMaintainsOutperform Aug 2021KeybancMaintainsOverweight View More Analyst Ratings for ITT View the Latest Analyst Ratings read more...

ITT drives growth with acquisitions, strong demand across segments and shareholder returns despite higher costs and currency headwinds....

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....

Here is how Federal Signal (FSS) and ITT (ITT) have performed compared to their sector so far this year....

--Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne compared with placebo. --Denifanstat (ASC40) demonstrated a favorable safety and tolerability profile. Treatment emergent adverse events......

Latest Ratings for ITT DateFirmActionFromTo Dec 2021B of A SecuritiesUpgradesNeutralBuy Aug 2021OppenheimerMaintainsOutperform Aug 2021KeybancMaintainsOverweight View More Analyst Ratings for ITT View the Latest Analyst Ratings read more...

Here is how Federal Signal (FSS) and ITT (ITT) have performed compared to their sector so far this year....

ITT (ITT) possesses solid growth attributes, which could help it handily outperform the market....

ITT (ITT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....